Travere Therapeutics, Inc.
TVTX
$17.92
$0.130.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 40.03% | 9.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 40.03% | 9.29% | |||
| Cost of Revenue | -1.33% | -20.20% | |||
| Gross Profit | 110.73% | 196.69% | |||
| SG&A Expenses | 4.64% | 4.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.16% | -7.24% | |||
| Operating Income | 70.36% | 28.08% | |||
| Income Before Tax | 69.08% | 31.74% | |||
| Income Tax Expenses | -48.72% | 154.17% | |||
| Earnings from Continuing Operations | 69.06% | 31.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 69.06% | 31.59% | |||
| EBIT | 70.36% | 28.08% | |||
| EBITDA | 104.57% | 36.77% | |||
| EPS Basic | 69.27% | 35.66% | |||
| Normalized Basic EPS | 69.28% | 34.27% | |||
| EPS Diluted | 69.27% | 35.66% | |||
| Normalized Diluted EPS | 69.28% | 34.27% | |||
| Average Basic Shares Outstanding | 0.67% | 6.32% | |||
| Average Diluted Shares Outstanding | 0.67% | 6.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||